Impact of the AurkA Phe31-Ile polymorphism as a predictive marker on the succeptibility of HNSCC patients to Cetuximab therapy
Author(s) -
Annekathrin Roth,
John Muth,
Guido Piontek,
Maria Buchberger,
Matthias Wirth,
Anja Pickhard
Publication year - 2019
Publication title -
laryngo-rhino-otologie
Language(s) - English
Resource type - Conference proceedings
eISSN - 1438-8685
pISSN - 0935-8943
DOI - 10.1055/s-0039-1686058
Subject(s) - cetuximab , kinase , cancer research , oncology , predictive marker , medicine , antibody , biology , monoclonal antibody , immunology , cancer , genetics
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom